Stock AnalizIcon PLC ICLR
Biotechnology: Commercial Physical & Biological Resarch · IPO 1998 · data as of November 13, 2026
Icon PLC (ICLR) is a healthcare company listed in the US with a market value of about $14.9B. In the twelve months to September 30, 2026 it had revenue of $8.2B and net income of $449M, a net margin of 5.4%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (1/5).
Key numbers: a P/E of 77.9, a price to free cash flow of 17.4, 5-year revenue growth of 24% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 27% below the current price.
Score: 1.8 / 5
Checks passed
- P/FCF below 20
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
- 20% to 100% of free cash flow returned to shareholders
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2B | $8.3B | $8.2B | $8.1B | $7.7B | $5.5B | $2.8B | $2.8B | $2.6B | $1.8B | $1.7B |
| Net income | $449M | $229M | $739M | $554M | $505M | $153M | $332M | $374M | $323M | $281M | $262M |
| Free cash flow | $857M | $862M | $1.1B | $1.0B | $421M | $735M | $527M | $374M | $220M | $338M | $217M |
| EPS (diluted) | $5.80 | $3.00 | $9.65 | $7.24 | $6.60 | $2.00 | $4.34 | $4.88 | $4.21 | $3.68 | $3.42 |
| Net margin | 5.4% | 2.8% | 9.0% | 6.9% | 6.5% | 2.8% | 11.9% | 13.3% | 12.4% | 16.0% | 15.7% |
| ROIC | — | 3.1% | 7.3% | 6.6% | 5.3% | 2.2% | 15.0% | 18.4% | 19.4% | 18.9% | 21.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 17 analysts is $231.29, 19% above the current price; targets range from $180.00 to $268.00; the consensus rating is “Buy”; expected EPS is $10.59 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Icon’s P/E ratio?
About 77.9, based on the last twelve months of diluted earnings per share (forward P/E about 17.2).
Is Icon stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 27% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Icon pay a dividend?
Not currently.
Is Icon a good stock to buy?
We do not give buy or sell advice. Icon scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.